<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>DISEASE CHARACTERISTICS: <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> (<z:hpo ids='HP_0002667'>nephroblastoma</z:hpo>), an embryonal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> of the kidney, is the most common <z:e sem="disease" ids="C0022665" disease_type="Neoplastic Process" abbrv="">renal tumor</z:e> of childhood </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> usually presents as an abdominal mass in an otherwise apparently healthy child </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> has the potential for both local and distant spread </plain></SENT>
<SENT sid="3" pm="."><plain>Approximately 5%-10% of children with <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> have bilateral or multicentric <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The average age at presentation is 42-47 months for children with unilateral <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> and 30-33 months for those with bilateral <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Current models of <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> development propose that a genetic mutation predisposes to <z:hpo ids='HP_0100880'>nephrogenic rests</z:hpo> (benign foci of embryonal kidney cells that persist abnormally into postnatal life) </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0100880'>Nephrogenic rests</z:hpo> are characterized as intralobar or perilobar </plain></SENT>
<SENT sid="7" pm="."><plain>In general, intralobar rests (usually single lesions within the renal lobe, renal sinus, or calyceal walls) are associated with the WAGR (<z:hpo ids='HP_0002667'>Wilms tumor</z:hpo>-<z:hpo ids='HP_0000526'>aniridia</z:hpo>-<z:hpo ids='HP_0000078'>genital anomalies</z:hpo>-retardation) syndrome and <z:e sem="disease" ids="C0950121" disease_type="Disease or Syndrome" abbrv="">Denys-Drash syndrome</z:e> (DDS) </plain></SENT>
<SENT sid="8" pm="."><plain>In general, perilobar rests (usually multiple lesions in the periphery of the renal lobe) are associated with <z:e sem="disease" ids="C0004903" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Beckwith-Wiedemann syndrome</z:e> (BWS) and hemi-<z:mpath ids='MPATH_159'>hypertrophy</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>However, the association between type of <z:hpo ids='HP_0100880'>nephrogenic rest</z:hpo> and predisposition syndrome is not absolute </plain></SENT>
<SENT sid="10" pm="."><plain>DIAGNOSIS/TESTING: The workup of a child with suspected <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> begins with appropriate diagnostic imaging studies </plain></SENT>
<SENT sid="11" pm="."><plain>Ultrasonography is the recommended first-line test because it provides a panoramic view of the abdomen </plain></SENT>
<SENT sid="12" pm="."><plain>Computed tomography (CT) can also visualize pelvic and abdominal structures as well as lymph nodes </plain></SENT>
<SENT sid="13" pm="."><plain>Magnetic resonance imaging (MRI) may facilitate the distinction between <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> and <z:hpo ids='HP_0100880'>nephrogenic rests</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>The definitive diagnosis of <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> can be made only by surgical resection or biopsy </plain></SENT>
<SENT sid="15" pm="."><plain>CAUSES: A germline mutation is thought to be the cause of about 10%-15% of <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> </plain></SENT>
<SENT sid="16" pm="."><plain>WT1 germline mutations give rise to <z:e sem="disease" ids="C0206115" disease_type="Disease or Syndrome" abbrv="WAGRO">WAGR syndrome</z:e>, DDS, Frasier syndrome, and isolated <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> (i.e., <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> with no evidence of an underlying syndrome) </plain></SENT>
<SENT sid="17" pm="."><plain>Epigenetic and genomic alterations of chromosome 11p15 give rise to BWS </plain></SENT>
<SENT sid="18" pm="."><plain>Approximately 1%-2% of individuals with <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> have at least one relative also diagnosed with <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo>; however, the underlying genetic mechanisms are usually not known </plain></SENT>
<SENT sid="19" pm="."><plain>Linkage analysis has mapped <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> predisposition genes to 17q (locus name FWT1) and 19q (locus name FWT2) </plain></SENT>
<SENT sid="20" pm="."><plain>Because in some families the <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> phenotype does not show linkage to WT1, FWT1, or FWT2, the existence of one or more other genes in which mutations cause familial <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> is likely </plain></SENT>
<SENT sid="21" pm="."><plain>GENETIC COUNSELING: If a proband has syndromic <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo>, genetic counseling for the specific syndrome is appropriate </plain></SENT>
<SENT sid="22" pm="."><plain>Nonsyndromic <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> most frequently occurs as a simplex case (i.e., a single occurrence in a family) </plain></SENT>
<SENT sid="23" pm="."><plain>Empiric risks to the sibs of a proband who is a simplex case are unknown but likely low; empiric risks to the offspring of a proband who is a simplex case are not increased </plain></SENT>
<SENT sid="24" pm="."><plain>Prenatal diagnosis for pregnancies at 50% risk of inheriting a WT1 or 11p15 genomic alteration from a parent is possible when the mutation and/or genetic mechanism in the family is known </plain></SENT>
<SENT sid="25" pm="."><plain>MANAGEMENT: Treatment of manifestations: Includes surgery, chemotherapy, and for some individuals, radiation therapy </plain></SENT>
<SENT sid="26" pm="."><plain>Surgery, a cornerstone of treatment, is performed at the time of diagnosis or after 4-8 weeks of preoperative chemotherapy </plain></SENT>
<SENT sid="27" pm="."><plain>Because <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> can spread to the lungs, preoperative chest radiography or chest CT scans are imperative </plain></SENT>
<SENT sid="28" pm="."><plain>Nephron-sparing surgery is routinely advocated for those with bilateral <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> </plain></SENT>
<SENT sid="29" pm="."><plain>Chemotherapy includes <z:chebi fb="0" ids="28445">vincristine</z:chebi> and dactinomycin for stage I and II favorable histology <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> and <z:chebi fb="0" ids="28445">vincristine</z:chebi>, dactinomycin, and <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> for stage III or IV favorable histology disease </plain></SENT>
<SENT sid="30" pm="."><plain>Treatment for anaplastic <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> includes <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> or ifosfamide, <z:chebi fb="0" ids="4911">etoposide</z:chebi>, and <z:chebi fb="2" ids="31355">carboplatin</z:chebi> </plain></SENT>
<SENT sid="31" pm="."><plain>After surgery children with advanced disease (stage III or IV) undergo radiation therapy </plain></SENT>
<SENT sid="32" pm="."><plain><z:hpo ids='HP_0003774'>End-stage renal disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>) is treated initially with dialysis, followed by renal transplantation when possible </plain></SENT>
<SENT sid="33" pm="."><plain>Surveillance: (1) For children with BWS or isolated <z:hpo ids='HP_0001528'>hemihypertrophy</z:hpo>: abdominal ultrasound examination every three months until age eight years </plain></SENT>
<SENT sid="34" pm="."><plain>(2) For children with <z:e sem="disease" ids="C0206115" disease_type="Disease or Syndrome" abbrv="WAGRO">WAGR syndrome</z:e>, sibs of an individual with familial <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo>, and offspring of survivors of bilateral <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo>: regular screening by abdominal ultrasound examination until age five to seven years </plain></SENT>
<SENT sid="35" pm="."><plain>(3) For those who have completed therapy for <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo>: renal ultrasound examination every three months for metachronous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> until age seven years </plain></SENT>
<SENT sid="36" pm="."><plain>(4) For <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>: in individuals with <z:e sem="disease" ids="C0206115" disease_type="Disease or Syndrome" abbrv="WAGRO">WAGR syndrome</z:e>, DDS, and GU anomalies: at least annual urinalysis, blood pressure measurement, and serum chemistries (including BUN and <z:chebi fb="0" ids="16737">creatinine</z:chebi>) </plain></SENT>
</text></document>